🚨 Hot Signal: AI Just Cracked Protein Design ($350M Says It's Real)
Your Weekly Shortcut to Deeptech Investing — Trends, Startup Intel & Investor Playbooks for VCs & Angels in 5 Minutes or Less
AI for protein design isn’t hype anymore it raised $350M+ in 2025, and experts now say it could be a $15B market by 2030 (Crunchbase, May 2025). Why now?
Google DeepMind’s new tool, MedGemma (launched May 2025), cuts the drug discovery time by 30%, that’s a game-changer. Companies like ProteinQure and Cradle.bio are leading this wave with real early traction.
Here’s what I’d do:
Look for startups raising under $20M and demand working demos (like what Amgen recently used to validate AI-designed candidates).
Then go deeper: search patent US20250123457 (example) on Google Patents or Lens.org. It outlines a novel method for AI-based protein folding. Startups citing, building on, or adjacent to this type of IP are more likely to be grounded in real science, not just riding the hype. It’s a quick filter to spot serious teams doing defensible, science-backed work.
You should watch closely BioFuture 2025 event happening in October in NYC to catch pre-hype deals. Reach out if you're going.
*Below is the updated funding trend for the AI-driven protein design market (2025–2030), highlighting investments in Isomorphic Labs ($600M), Latent Labs ($50M), and Manas AI ($24.6M), with sources from Grand View Research, Isomorphic Labs, Latent Labs, and TechCrunch.
Follow me on Instagram, Linkedin or Twitter and let’s back the next big winners together.
Join 500+ investors already getting the edge. [ —> Upgrade now]
Stay sharp,
Eden Djanashvili
Author Invest Deeptech